Original article

Quantification of peripheral blood CD34+ cells prior to stem cell harvesting by leukapheresis: a single center experience

Natália Emerim Lemos a,b,*, Mariela Granero Farias b, Francyne Kubaski b, Luciana Scotti b, Tor Gunnar Hugo Onsten b, Leticia de Almeida Brondani b, Sandrine Comparsi Wagner a,c, Leo Sekine b

a Universidade Feevale, Novo Hamburgo, RS, Brazil
b Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
c Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil

Article history:
Received 21 December 2017
Accepted 30 January 2018
Available online 15 March 2018

Keywords:
Transplantation
Apheresis
CD34+ progenitor cells
Flow cytometry

ABSTRACT

Background: Due to laboratory logistic issues, our center has traditionally scheduled peripheral blood stem cell harvests based on timing from the start of mobilization. This has proved to be useful in some cases, but also resulted in many fruitless harvests due to poor mobilization. In order to improve the efficiency of collections and compare the effectiveness of peripheral blood CD34+ cells as a predictor with data from other reports, this study analyzed the implementation of this routine.

Methods: Peripheral blood and leukapheresis samples were quantified by flow cytometry and the association between these parameters was assessed.

Results: Sixty-six consecutive leukapheresis samples were collected from 34 patients after the collection of peripheral blood samples for CD34+ quantification. A moderate positive correlation was observed between peripheral blood CD34+ cell count and total CD34+ cell count/kg (r = 0.596; p-value = 0.001). A multivariable regression model also confirmed this association and allowed the estimation that for every increase in five CD34+ cells/μL in the peripheral blood, a mean increase of 0.38 × 10⁶ CD34+ cells/kg could be predicted. Demographic characteristics, baseline comorbidities and mobilization regimen did not influence final CD34+ cell count in this sample.

Conclusions: As observed in other centers, quantification of peripheral blood CD34+ progenitor cells is a strong predictor of effectiveness to guide stem cell harvesting. Due to the results of this study, a modification in the peripheral blood stem cell harvesting logistics was implemented at our center in order to incorporate this routine.

© 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license http://creativecommons.org/licenses/by-nc-nd/4.0/.

* Corresponding author at: Rua Ramiro Barcelos, 2350, Santa Cecília, Porto Alegre CEP: 90035-903, RS, Brazil.
E-mail address: natiemerim@hotmail.com (N.E. Lemos).

https://doi.org/10.1016/j.hct.2018.01.002
2531-1379 © 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Hematopoietic stem cell transplantation (HSCT) is a treatment modality that allows the administration of high intensity chemotherapy (conditioning) without causing permanent myeloablation and the infusion of hematopoietic stem cells (both autologous or allogeneic). Hematopoietic progenitor cells may be obtained either from bone marrow (BM), peripheral blood (PB) or umbilical cord blood (UCB). The widespread use of bone marrow as a source of stem cells for the treatment of hematological, oncological, hereditary and immunological diseases, derives from more than a century of research. Periperal cells are collected using an apheresis machine after being mobilized from the bone marrow to PB. Currently, this technique is applied in more than 90% of autologous bone marrow transplants (BMT) and in approximately 70% of allogeneic BMT. These cells, known as peripheral blood stem cells (PBSCs), became the preferred source for autologous HSCT. The advantages of PBSCs over BM stem cells in autologous settings include faster hematopoietic recovery, better immunological reconstitution and a relatively easy collection process. The use of PBSC in allogeneic settings is still not the first choice due to its impact on the modulation of graft-versus-host disease (GVHD).

Hematopoietic progenitor cells typically express the CD34 antigen on the cell membrane and this has been correlated with colony forming units in cell cultures, which is considered the gold standard for stem cell quantification. Furthermore, the quantification of CD34+ cells by flow cytometry is widely used in the clinical practice as an indirect indicator of hematopoietic progenitor cells. Under normal conditions, CD34+ cells in PB range from 0.01 to 0.05%; in the BM, the concentration is usually less than 1% of normal mononuclear cells. The number of progenitor cells to be infused to reach a proper hematopoietic recovery is still controversial; however, a minimum of 2–5 × 10^6 CD34+ cells/kg of body weight is required to achieve consistent engraftment.

Classical strategies to mobilize PBSCs include the administration of hematopoietic growth factors such as the granulocyte colony-stimulating factor (G-CSF), filgrastim, which is the most used protocol in our setting. The use of G-CSF may cause side effects, such as bone pain, headache, and low-grade fever, although these symptoms rarely affect PBSC harvesting. Other centers use different colony-stimulating factors, such as sargramostim and stem cell factor, as well as other adjuvant substances, such as plerixafor, and the traditional regimen generally combining chemotherapy (CT) with cyclophosphamide, and G-CSF. PBSCs for autologous transplantation are usually collected by leukapheresis during hematological recovery after CT and/or during the administration of mobilizing agents. However, the kinetics of the CD34+ cell concentration in the PB is difficult to estimate and varies depending on the mobilization regimen used.

Predictive factors for an effective harvesting have been broadly studied. These include parameters obtained prior to the beginning of the procedure that influence the efficiency of harvesting CD34+ cells. The total leukocyte count, number of monocytes and lymphocytes, and percentage of circulating immature cells of the granulocytic lineage have all been mentioned as possible predictive factors for apheresis collection. Among these factors, the monitoring of PB CD34+ cell concentrations by flow cytometry has emerged as a reliable method to predict the success/failure rate of collections. The concentrations obtained by leukapheresis are directly correlated with the quantification of CD34+ cells in PB, however the final yield obtained in the apheresis product is, to some extent, variable. A cut-off for CD34+ cell count of >10 to 20 × 10^6/mL is usually considered a reasonable cut-off value for an effective PBSC collection.

Traditionally at the HCPA, PB stem cell harvesting was scheduled based on median days to CD34+ peak cell concentration (at around 4–5 days of mobilization exclusively with filgrastim, or on the 11th day following a cyclophosphamide-based regimen). This routine was established due to laboratory limitations in respect to the availability of flow cytometry and proved adequate in a significant number of patients. However, in up to 20% of patients, this strategy resulted in futile procedures due to poor mobilization. In order to validate a new routine and assure its effectiveness in preventing unnecessary procedures, a strategy was applied at the HCPA to collect a PB sample to quantify peripheral CD34+ cells prior to the apheresis collection. This study describes the feasibility of quantifying CD34+ cells in the PB prior to apheresis in order to improve the success rate of apheresis collections in a local sample of patients.

Methods

This study was conducted in the Apheresis Unit and Clinical Pathology Department of the HCPA and was approved by the local Research Ethics Committee (number: 12-0326). All the enrolled patients signed written informed consent forms before participating in the research protocol. The study was conducted in accordance with the Helsinki Declaration as revised in 2008. All patients referred for autologous bone marrow transplantation were included irrespective of underlying disease and compliance with the mobilization protocol for apheresis. No exclusion criterion was applied. Results for the quantification of CD34+ cells in apheresis samples were obtained by the previously established routine assessment of PBSC collections. CD34+ progenitor cells were quantified by flow cytometry using the International Society of Hemotherapy and Graft Engineering (ISHAGE) protocol.

PB samples for CD34+ cell counts were collected from each patient immediately before beginning leukapheresis. Samples were kept at room temperature (25°C) for 1 h prior to CD34+ quantification. PB CD34+ cells were counted with a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) using CD45 and CD34 clone 8G12 monoclonal antibodies (Becton Dickinson, San Jose, CA, USA) conjugated with the fluorochromes fluorescein isothiocyanate and phycoerythrín, respectively, according to the ISHAGE protocol to identify CD34+ cells by flow cytometry. After the addition of monoclonal antibodies, cells were homogenized, incubated for 15 min at room temperature, and the red blood cells were
lysed and washed with phosphate buffered saline (PBS). Subsequently, cells were resuspended in PBS and counted by flow cytometry. Two hundred thousand CD45+ events were acquired, in order to ensure the counting of at least 100 CD34+ cells according to recommendations of the ISHAGE protocol (Figure 1). Results were obtained and were analyzed using the Cell Quest software (Becton Dickinson, San Jose, CA, USA).

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software version 20.0 (SPSS, Chicago, IL, USA). Variables were described depending on their distributions and normality was assessed with the Shapiro–Wilk test. Continuous variables were compared using the Pearson or Spearman correlation as indicated by their distributions. A linear mixed regression model was assembled to evaluate multiple variables of interest. A p-value < 0.05 was considered statistically significant.

Results

Sixty-six consecutive leukapheresis samples from 34 patients were analyzed. The first leukapheresis was performed four days after the beginning of G-CSF mobilization. Some patients underwent an alternative regimen including CT and G-CSF. In these cases, samples were collected 11 days after the beginning of the treatment.

Patient baseline characteristics are shown in Table 1. The mean age was 39 years (range: 1–68 years), the proportion of males was 52.9% and the most prevalent indication for autotransplantation was multiple myeloma (MM) (44.1%).

The percentage of CD34+ cells was higher in apheresis compared to PB samples (0.15% vs. 0.03%, respectively; p-value < 0.001). Accordingly, the mean total leukocytes was also higher in apheresis compared to PB samples (155,794/μL vs. 35,563/μL, respectively; p-value < 0.001). This proves the capacity of the apheresis system in centrifugation and concentration of the patient's buffy coat.

Correlations between variables of interest are shown in Table 2. A moderate positive correlation was found between CD34+ cells/μL from PB and the total PB CD34+ cells/kg body weight/procedure (r = 0.596; p-value < 0.001; Figure 2). In an attempt to analyze sensitivity, the persistence of this association was evaluated while stratifying data for different baseline characteristics; this correlation remained significant (p-value < 0.01) for subgroups of gender, diagnosis and mobilization regimen.

Finally, a multivariable model approach was used to evaluate different possible predictors of harvest results. In a forward stepwise manner, univariate models were assembled to exclude variables that were not significant considering a p-value < 0.2 (Table 3). The only predictor that persisted

---

**Figure 1** – Gates strategy used according to recommendations of the International Society of Hemotherapy and Graft Engineering (ISHAGE). (A) Region positive for CD45 cells representing all leucocytes (R1 gate). (B) Positive for CD34 from immature cells (R2 gate). (C) Combined events of R1 and R2 with Gate R3 selecting CD45+ low complexity cells. (D) Cells selected by FSC/SSC and the percentage of CD34+ cells was determined (R4 gate).
Table 1 – Characteristics of 66 peripheral blood cell harvests of 34 patients.

| Characteristic                  | Distribution            |
|--------------------------------|-------------------------|
| Gender (male) – n (%)\(^a\)   | 18 (52.9)               |
| Age – median (range)\(^b\)    | 39 (1–68)               |
| Diagnosis – n (%)\(^c\)       |                         |
| Multiple myeloma               | 15 (44.11)              |
| Neuroblastoma                  | 5 (14.7)                |
| Non-Hodgkin lymphoma           | 4 (11.76)               |
| Hodgkin lymphoma               | 4 (11.76)               |
| Testicular neoplasms           | 3 (8.85)                |
| Wilm’s tumor                   | 2 (5.89)                |
| Amyloidosis                    | 1 (2.94)                |
| Mobilization regimen – n (%)\(^d\) |                     |
| G-CSF                          | 33 (97.06)              |
| Cyclophosphamide plus G-CSF   | 1 (2.94)                |
| PB cell count – mean (SD)\(^e\) | 35,563.38/µL            |
| (range)                        | (31,240.02–39,886.75)   |
| PB CD34\(^+\) cell percentage – median (range)\(^f\) | 0.03% (0.0–0.27)       |
| PB CD34\(^+\) absolute count – median (range)\(^g\) | 10.2/µL (0.0–124.4)    |
| Leukapheresis leukocyte count – median (range)\(^h\) | 155,794/µL             |
| (range)                        | (29,860–507,760)        |
| Leukapheresis CD34\(^+\) cell percentage – median (range)\(^i\) | 0.15% (0.02–0.79)     |
| Leukapheresis CD34\(^+\) absolute count – median (range)\(^j\) | 156.9/µL               |
| (range)                        | (10.1–2601.1)           |
| Final PB harvest yield (per procedure) – median (range)\(^k\) | 1.4 × 10\(^6\) CD34\(^+\) cells/kg (0.05–11.08) |

PB: peripheral blood.
\(^a\) 34 patients.
\(^b\) 66 procedures.

Discussion

The CD34\(^+\) cell count has been the standard method to quantify stem cells for decades now and its use to guide harvesting time has been concretely established.\(^{10,16}\) The majority of studies showed a positive and reliable correlation between PB and apheresis CD34\(^+\) cell content, which indicates that monitoring the PB is effective to predict harvesting results. In the present study, we found a moderate correlation similar to previously described reports.\(^{10,17}\) This correlation was independent of gender, diagnosis or mobilization regimen. The MM patient subgroup showed the highest correlation coefficient through this stepwise exclusion was the PB CD34\(^+\) cell count (p-value < 0.001) and according to the regression equation, each increase in five cells/µL resulted in a mean increase of 0.38 × 10\(^6\) CD34\(^+\) cells/kg body weight/per procedure.

Table 2 – Correlation analysis for quantitative measures of peripheral blood hematopoietic stem cell harvests (66 procedures).

| Variables correlated (total sample and stratified) | Correlation coefficient | p-Value |
|----------------------------------------------------|-------------------------|---------|
| PB CD34\(^+\) absolute count/µL                    | Total CD34\(^+\) cell count/kg (per procedure) | 0.596\(^a\) | <0.001 |
| Gender                                             |                         |         |
| Male                                               | 0.605\(^a\)            | <0.001 |
| Female                                             | 0.588\(^a\)            | <0.001 |
| Diagnosis                                          |                         |         |
| Multiple myeloma                                   | 0.723\(^a\)            | <0.001 |
| Other diseases                                     | 0.514\(^b\)            | 0.002  |
| Mobilization regimen                               |                         |         |
| G-CSF                                              | 0.573\(^a\)            | <0.001 |
| PB leukocyte count                                 | PB CD34\(^+\) cell percentage | −0.077\(^a\) | 0.541 |
| Collection day (first, second and third)           | PB CD34\(^+\) absolute count | −0.296\(^b\) | 0.003 |
| Leukapheresis leukocyte count                       | Final PB harvest yield (per procedure) | 0.260\(^b\) | 0.035 |

PB: peripheral blood; G-CSF: granulocyte colony-stimulating factor.
\(^a\) Spearman Rho.
\(^b\) Kendall Tau-b.
within the sample, according to their low expected failure rate.\textsuperscript{24,25}

A negative correlation was seen between the total leukocyte count and the percentage of CD34\(^+\) cells, indicating that the total leukocyte count should not be used as a predictor of effective harvesting. A negative correlation between the absolute CD34\(^+\) count and collection day was also seen. The number of CD34\(^+\) cells decreased with time even if the patient was still receiving G-CSF. Thus, the first collection had higher yields of CD34\(^+\) cells.

Regression analysis allowed the estimation that for every increase of five CD34\(^+\) cells/\(\mu\)L in PB, a mean increase in 0.38 \(\times\) \(10^6\) CD34\(^+\) cells/kg body weight could be expected. Based on this result, a cut-off value of 15 cells/\(\mu\)L in the PB should be used for a minimum of 1.0 \(\times\) \(10^6\)/kg of body weight CD34\(^+\) cells to be collected in one procedure (3 \(\times\) 0.38 = 1.14). The implementation of this strategy in patient evaluation prior to harvesting reduced costs and extra procedures (e.g. higher doses of mobilizing factors and longer wait time for re-collection) performed on the patient.

Even taking into consideration the different alternatives of mobilization for transplantation, there are still many patients who do not achieve the minimum number of cells. This is due to known or unknown factors related to the primary condition of the patient or the mobilization regimen used. Szmigielska-Kaplon et al.\textsuperscript{26} demonstrated that there are molecular changes that can be related to the difficulty of collecting the stem cells according to the primary disease. Accordingly, many patients do not achieve an ideal minimum number of collected CD34\(^+\) cells for transplantation (1.5–3 \(\times\) \(10^6\)/kg body weight).\textsuperscript{27} Sometimes different mobilization regimens are required based on the underlying disease and prior treatment. The G-CSF or G-CSF plus CT mobilization regimen is widely used,\textsuperscript{28} but it has a relatively high failure rate of from 5 to 40%.\textsuperscript{29} This failure occurs particularly in patients with non-Hodgkin lymphoma (NHL) with a failure rate of nearly 26%, while MM has a failure rate of 6%.\textsuperscript{24,25} This may explain our finding that patients with MM have higher CD34\(^+\) cell counts than patients with other diseases.

Pusic and Wucherter\textsuperscript{24,28} analyzed 840 patients mobilized with CT and G-CSF. These authors demonstrated that the failure rate of mobilization decreased with the implementation of this treatment regimen (10.8%). Thus, CT combined with growth factors may improve the mobilization of progenitor cells to the PB.

Plerixafor is another mobilizing agent with a synergistic effect when associated with G-CSF and may increase the number of CD34\(^+\) cells by up to 3.8 times.\textsuperscript{26} One disadvantage of plerixafor is that mobilization is rapid with its effect disappearing within 24 h. Moreover, it has a high cost, which hinders its use in our setting. In Europe, a study conducted with 508 patients (270 NHL, 54 Hodgkin’s lymphoma and 256 MM) found that plerixafor was efficient in cell collection (\(>2 \times 10^6\)/kg body weight) in 64.8% of NHL patients, 81% of Hodgkin’s lymphoma patients and 81.6% of MM patients.\textsuperscript{25} Plerixafor has limitations and disadvantages, but it is a good alternative for patients with poor mobilization.

This study was limited by the sample size analyzed. Nonetheless, we believe that it is important to share the experience of our center, as it may be applied to other institutions to reduce collection failure. This strategy reduced costs and improved logistics. It is known that this methodology is already used comprehensively as standard routine, however regionally based data are lacking and it is important to compare this experience with that of other centers. The dual platform methodology could also have implicated some variability in the results.

**Conclusion**

In conclusion, in a local population of patients, PB CD34\(^+\) cell counts predicted PB stem cell harvests in large volume leukapheresis. Thus, the counting of PB CD34\(^+\) progenitor cells should be systematically used to guide stem cell harvesting by leukapheresis. This variable reliably predicted the final yield of PBSCs. This strategy led to an increase in the success rate of apheresis collections making this procedure more efficient, lowering the costs, and consequently eliminating extra procedures of patients.

**Funding**

This work was supported by Fundo de Incentivo à Pesquisa e Eventos (FIPE-HCPA).

**Conflicts of interest**

The authors declare no conflicts of interest.

**REFERENCES**

1. Santos GW. History of bone marrow transplantation. Clin Haematol. 1983;12(3):611–39.
2. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 2011;46(4):485–501.
3. Milone G, Leotta S, Indelicato F, Mercurio S, Moschetti G, Di Raimondo F, et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma.
results depend on degree of previous pretreatment. Bone Marrow Transplant. 2003;31(9):747–54.
4. Kessinger A, Sharp JC. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant. 2003;31(5):319–29.
5. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992;1(4):329–41.
6. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373–81.
7. Scott MA, Gordon MY. In search of the haematopoietic stem cell. Br J Haematol. 1995;90(4):738–43.
8. Sutherland DR, Keating A, Nayyar R, Anania S, Stewart AK. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol. 1994;22(10):1003–10.
9. Barnett D, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol. 1999;21(5):301–8.
10. Trebeden-Negre H, Rosenzwaig M, Tanguy ML, Lefrere F, Azar N, Heshmati F, et al. Delayed recovery after autologous peripheral hematopoietic cell transplantation: potential effect of a high number of total nucleated cells in the graft. Transfusion. 2008;50(12):2649–59.
11. Castro Junior CG. Análise clínica e epidemiológica do transplante de medula óssea no Serviço de Oncologia Pediátrica do Hospital de Clínicas de Porto Alegre: Universidade Federal do Rio Grande do Sul; 2002 [Internet]. Available from: http://www.lume.ufgrs.br/bitstream/handle/10183/1568/000351785.pdf?sequence=1
12. Duncan N, Hewetson M, Powles R, Raje N, Mehta J. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1996;17(6):1175–8.
13. Fontao-Wendel R, Lazar A, Melges S, Altobeli C, Wendel S. The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother. 1999;8(3):255–62.
14. Gutensohn K, Magens MM, Kuehnl P, Zeller W. Increasing the economic efficacy of peripheral blood progenitor cell collections by monitoring peripheral blood CD34+ concentrations. Transfusion. 2010;50(3):656–62.
15. Davis BH, Foucar K, Szczarkowski W, Ball E, Witzig T, Foon KA, et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry. 1997;30(5):249–63.
16. Hollingsworth KL, Zimmerman TM, Karrison T, Oliver A, Williams SF. The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product. Cytotherapy. 1999;1(2):141–6.
17. Schots R, Van Riet I, Damiaens S, Flamant J, Lacor P, Staelens Y, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant. 1996;17(4):509–15.
18. Weeks FM, Yee GC, Bartfeld AA, Wingard JR. The true cost of bone marrow transplantation. Am J Med Sci. 1997;314(2):101–12.
19. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schraver AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14(4):116–24.
20. Kozuka T, Ikeda K, Teshima T, Kojima K, Matsuo K, Bessho A, et al. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion. 2002;42(11):1514–22.
21. Marques JF, Vigorito AC, Aranha FJ, Lorand-Metz I, Miranda EC, Lima Filho EC, et al. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield. Transfus Sci. 2000;23(2):91–100.
22. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, et al. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008;48(6):1106–14.
23. Sutherland DR, Anderson L, Keeney M, Nayyar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hemotherapy and Graft Engineering. J Hematother. 1996;5(3):213–26.
24. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16(4):490–9.
25. Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant. 2013;19(4):670–5.
26. Szmiętkowska-Kaplon A, Szemraj J, Hamara K, Robak M, Wolska A, Pluta A, et al. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20(7):986–91.
27. Chen AJ, Bains T, Murray S, Knight R, Shoop K, Bubalo J, et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant. 2012;47(12):1526–9.
28. Pusic I, Jiang SY, Landua S, Uly GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045–56.